NCT06315608View on ClinicalTrials.gov

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

March 1, 2026

Conditions
Amyotrophic Lateral SclerosisLou Gehrig DiseaseMotor Neuron DiseaseMotor Neuron Atrophy
Interventions
DRUG

MRG-001

MRG-001 is a clear liquid solution for subcutaneous injection

Sponsors

Lead Sponsor

MedRegen LLC
All Listed Sponsors
lead

MedRegen LLC

INDUSTRY

NCT06315608 - MRG-001 in Patients With Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter